Work

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies

Year: 2016

Type: article

Study design: Clinical Trial

Source: Breast Cancer Research and Treatment

DOI: 10.1007/s10549-016-3701-7

Authors: Amy Jo Chien, Alyson Cockerill, Craig Fancourt, Emmett Schmidt, Mark M. Moasser, Hope S. Rugo, Michelle E. Melisko, Andrew H. Ko, R. Katie Kelley, W. Michael Korn, Laura J. Esserman, Laura van‘t Veer, Christina Yau, Denise M. Wolf, Pamela N. Munster

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development

Award: UCSF-Kaiser Department of Research Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Program

OpenAlex ID: W2268975203

FWCI: 1.854

Cites: 35

Cited by: 32

Related to: 10